Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026
Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
Homerun Resources Inc. Announces Closing of Initial Tranche of Convertible Security Financing with the Lind Partners Under Engagements with Benchmark/StoneX
Premier American Uranium Identifies Multiple Mineralized Uranium Trends in Ongoing Drilling at Kaycee, Wyoming
Lahontan Announces 22% Increase in Mineral Resources at Santa Fe: 1,195,000 Au Eq oz Indicated, and 1,190,000 Au Eq oz Inferred
